-
1
-
-
0028275559
-
Ten-year incidence of visual loss in a diabetic population
-
Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101(6):1061-70
-
(1994)
Ophthalmology
, vol.101
, Issue.6
, pp. 1061-1070
-
-
Moss, S.E.1
Klein, R.2
Klein, B.E.3
-
2
-
-
63049133469
-
Diabetic retinopathy: A growing concern in an aging population
-
Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64(2):16-20
-
(2009)
Geriatrics
, vol.64
, Issue.2
, pp. 16-20
-
-
Paulus, Y.M.1
Gariano, R.F.2
-
3
-
-
40849137726
-
Clinically significant macular edema and survival in type 1 and type 2 diabetes
-
Hirai FE, Knudtson MD, Klein BE, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145(4):700-6
-
(2008)
Am J Ophthalmol
, vol.145
, Issue.4
, pp. 700-706
-
-
Hirai, F.E.1
Knudtson, M.D.2
Klein, B.E.3
-
4
-
-
79955852527
-
Pegaptanib octasodium for the treatment of diabetic macular edema
-
Schartman JP, Coney JM, Hornik JH, et al. Pegaptanib octasodium for the treatment of diabetic macular edema. Expert opin pharmacother 2011;12(8):1317-23
-
(2011)
Expert Opin Pharmacother
, vol.12
, Issue.8
, pp. 1317-1323
-
-
Schartman, J.P.1
Coney, J.M.2
Hornik, J.H.3
-
5
-
-
0031793875
-
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes
-
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105(10):1801-15
-
(1998)
Ophthalmology
, vol.105
, Issue.10
, pp. 1801-1815
-
-
Klein, R.1
Klein, B.E.2
Moss, S.E.3
Cruickshanks, K.J.4
-
6
-
-
0028915217
-
Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial
-
Diabetes Control and Complications Trial Research Group
-
Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61
-
(1995)
Ophthalmology
, vol.102
, pp. 647-661
-
-
-
8
-
-
0022347471
-
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1
-
Early Treatment Diabetic Retinopathy Study research group PMID: 2866759
-
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103(12):1796-806. PMID: 2866759
-
(1985)
Arch Ophthalmol
, vol.103
, Issue.12
, pp. 1796-1806
-
-
-
9
-
-
0027370108
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
The Diabetes Control and Complications Trial Research Group PMID: 8366922
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. PMID: 8366922
-
(1993)
N Engl J Med
, vol.329
, Issue.14
, pp. 977-986
-
-
-
10
-
-
79953299899
-
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
-
Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
-
(2011)
Ophthalmology
, vol.118
, Issue.4
, pp. 609-614
-
-
Elman, M.J.1
Bressler, N.M.2
Qin, H.3
-
11
-
-
62449171859
-
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema
-
Diabetic Retinopathy Clinical Research Network
-
Diabetic Retinopathy Clinical Research Network. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245-51
-
(2009)
Arch Ophthalmol
, vol.127
, Issue.3
, pp. 245-251
-
-
Beck, R.W.1
Edwards, A.R.2
Aiello, L.P.3
-
12
-
-
77952779304
-
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
-
Diabetic Retinopathy Clinical Research Network
-
Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064-77.e35
-
(2010)
Ophthalmology
, vol.117
, Issue.6
-
-
Elman, M.J.1
Aiello, L.P.2
Beck, R.W.3
-
14
-
-
0036959644
-
Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration
-
Eyetech Study Group
-
Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22(2):143-52
-
(2002)
Retina
, vol.22
, Issue.2
, pp. 143-152
-
-
-
17
-
-
84874874434
-
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
-
Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:495-501
-
(2013)
Clin Ophthalmol
, vol.7
, pp. 495-501
-
-
Thomas, M.1
Mousa, S.S.2
Mousa, S.A.3
-
18
-
-
77955657984
-
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
-
Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch clin exp ophthalmol 2010;248(7):915-30
-
(2010)
Graefes Arch Clin Exp Ophthalmol
, vol.248
, Issue.7
, pp. 915-930
-
-
Nicholson, B.P.1
Schachat, A.P.2
-
19
-
-
84867099927
-
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema
-
FAME Study Group
-
Peter A, Campochiaro PA, Brown DM, et al. FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Opthalmology 2012;119:2125-32
-
(2012)
Opthalmology
, vol.119
, pp. 2125-2132
-
-
Peter, A.1
Campochiaro, P.A.2
Brown, D.M.3
-
20
-
-
77749330682
-
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema
-
Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289-96
-
(2010)
Arch Ophthalmol
, vol.128
, Issue.3
, pp. 289-296
-
-
Haller, J.A.1
Kuppermann, B.D.2
Blumenkranz, M.S.3
-
21
-
-
84857260889
-
Ranibizumab: In diabetic macular oedema
-
Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs 2012;72(4):509-23
-
(2012)
Drugs
, vol.72
, Issue.4
, pp. 509-523
-
-
Frampton, J.E.1
-
22
-
-
84885022310
-
Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE extension study
-
Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013;120:2004-12
-
(2013)
Ophthalmology
, vol.120
, pp. 2004-2012
-
-
Lang, G.E.1
Berta, A.2
Eldem, B.M.3
-
23
-
-
84865593623
-
A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3
-
Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8):972-9
-
(2012)
Arch Ophthalmol
, vol.130
, Issue.8
, pp. 972-979
-
-
Rajendram, R.1
Fraser-Bell, S.2
Kaines, A.3
-
24
-
-
80052512394
-
A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections
-
van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31(8):1449-69
-
(2011)
Retina
, vol.31
, Issue.8
, pp. 1449-1469
-
-
Van Der Reis, M.I.1
La Heij, E.C.2
De Jong-Hesse, Y.3
-
25
-
-
84864444516
-
One-year outcomes of the da Vinci Study of VEGF. Trap-Eye in eyes with diabetic macular edema
-
Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF. Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658-65
-
(2012)
Ophthalmology
, vol.119
, Issue.8
, pp. 1658-1665
-
-
Do, D.V.1
Nguyen, Q.D.2
Boyer, D.3
-
26
-
-
25844513658
-
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema
-
Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57
-
(2005)
Ophthalmology
, vol.112
, Issue.10
, pp. 1747-1757
-
-
Cunningham, Jr.E.T.1
Adamis, A.P.2
Altaweel, M.3
-
27
-
-
22744446011
-
Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration
-
Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert opin pharmacother 2005;6(8):1421-3
-
(2005)
Expert Opin Pharmacother
, vol.6
, Issue.8
, pp. 1421-1423
-
-
Doggrell, S.A.1
-
28
-
-
32844458094
-
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A review
-
Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin ther 2006;28(1):36-44
-
(2006)
Clin Ther
, vol.28
, Issue.1
, pp. 36-44
-
-
Kourlas, H.1
Schiller, D.S.2
-
29
-
-
29644444716
-
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals
-
Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113(1):23-8
-
(2006)
Ophthalmology
, vol.113
, Issue.1
, pp. 23-28
-
-
Adamis, A.P.1
Altaweel, M.2
Bressler, N.M.3
-
30
-
-
79958012399
-
-
Sultan MB, Zhou D, Loftus J, et al. Macugen Study G. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118(6):1107-18
-
Macugen Study G. A Phase 2/3, Multicenter, Randomized, Double-masked, 2-year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema. Ophthalmology 2011
, vol.118
, Issue.6
, pp. 1107-1118
-
-
Sultan, M.B.1
Zhou, D.2
Loftus, J.3
-
32
-
-
77952506869
-
Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan- European experience
-
Sivaprasad S, Hykin P, Saeed A, et al. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: pan- European experience. Eye(Lond) 2010;24(5):793-8
-
(2010)
Eye(Lond)
, vol.24
, Issue.5
, pp. 793-798
-
-
Sivaprasad, S.1
Hykin, P.2
Saeed, A.3
-
33
-
-
84860156429
-
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors
-
Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(Suppl 1):2-10
-
(2012)
Ophthalmologica
, vol.227
, Issue.SUPPL. 1
, pp. 2-10
-
-
Chong, V.1
-
34
-
-
84904325881
-
Screening for visual impairment in older adults: Systematic review to update the 1996 US Preventive Services Task Force Recommendation
-
PMID: 20722170
-
Chou R, Dana T, Bougatsos C. Screening for visual impairment in older adults: systematic review to update the 1996 US Preventive Services Task Force Recommendation. U.S. Agency for Healthcare Research and Quality, Rockville, MD; 2009. Report No.: 09-05135-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. PMID: 20722170
-
U.S. Agency for Healthcare Research and Quality, Rockville, MD; 2009. Report No.: 09-05135-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, Formerly Systematic Evidence Reviews
-
-
Chou, R.1
Dana, T.2
Bougatsos, C.3
-
35
-
-
84899902749
-
Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE Extension Study
-
Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension Study. Ophthalmology 2014;121(5):1045-53
-
(2014)
Ophthalmology
, vol.121
, Issue.5
, pp. 1045-1053
-
-
Schmidt-Erfurth, U.1
Lang, G.E.2
Holz, F.G.3
|